Target intelligence / Profile preview

Essential meiotic structure-specific endonuclease subunit 2 (EME2)

Target
EME2
Molecular classification
Enzyme, Structure-specific endonuclease, DNA repair protein
01

Overview

Essential meiotic structure-specific endonuclease subunit 2 (EME2) is the non-catalytic regulatory partner in a heterodimeric DNA structure-specific endonuclease complex with MUS81. This complex functions as an XPF-family enzyme that cleaves branched DNA structures—such as 3’-flap structures, replication forks, and Holliday junctions—that arise during replication stress, homologous recombination, and DNA repair. EME2's primary role is to promote genome stability by facilitating the resolution of recombination intermediates and enabling proper chromosome segregation during mitosis and meiosis[1][2][3][6]. In vertebrates, the MUS81-EME2 complex demonstrates enhanced activity and a broader substrate spectrum compared to MUS81-EME1, efficiently processing recombination and replication intermediates including intact Holliday junctions and D-loops. Disruption or impaired regulation of EME2 function can contribute to genomic instability, a key hallmark of cancer, and other diseases linked to defective DNA repair[6]. Note: No direct evidence was found for approved therapeutic drugs or diagnostic biomarkers targeting EME2 specifically. Its enzymatic function and interaction with MUS81 make it of interest for cancer biology and potentially as a drug target, but there are currently no known specific inhibitors or clinical tools directly targeting EME2[6].

Other names
Structure-specific endonuclease subunit EME2FLJ00151SLX2BSLX2 structure-specific endonuclease subunit homolog Bgs125essential meiotic endonuclease 1 homolog 2probable crossover junction endonuclease EME2homolog of yeast EME1 endonuclease 2
02

Biological functions

DNA repairResolution of Holliday junctionsMaintenance of genome stabilityProcessing of stalled replication forks
03

Disease associations

Cancer (through genome instability and role in replicative stress)Mitochondrial disorders (such as Leigh syndrome, combined oxidative phosphorylation deficiency 32)
04

Safety considerations

Potential genome instability if dysregulatedRole in carcinogenesis when functionally impaired

Beyond the preview

Go deeper on Essential meiotic structure-specific endonuclease subunit 2 (EME2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Essential meiotic structure-specific endonuclease subunit 2 (EME2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call